Tnkase Related Published Studies
Well-designed clinical trials related to Tnkase (Tenecteplase)
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design. [2011.08]
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in
acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design. [2011]
TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters. [2010.12]
Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. [2010.04]
A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3. [2010.04]
Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. [2010.03]
ST segment resolution in patients with tenecteplase-facilitated percutaneous coronary intervention versus tenecteplase alone: Insights from the Combined Angioplasty and Pharmacological Intervention versus Thrombolysis ALone in Acute Myocardial Infarction (CAPITAL AMI) trial. [2010.01]
TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of
tenecteplase for restoration of function in dysfunctional central venous
catheters. [2010]
Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a
prematurely terminated randomized clinical trial. [2010]
A phase III, randomized, double-blind, placebo-controlled study of tenecteplase
for improvement of hemodialysis catheter function: TROPICS 3. [2010]
Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. [2009.10.13]
[An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction] [2009.06]
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. [2005.07]
International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest: the Thrombolysis in Cardiac Arrest (TROICA) Study. [2005.05]
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. [2004.08.10]
Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. [2004.06.15]
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. [2004.06]
Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. [2004.02.18]
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. [2003.10.01]
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. [2003.07.15]
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. [2003.07]
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. [2003.04.16]
Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction. [2003.02]
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. [2002.04.15]
Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. [2001.12.01]
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. [2000.05]
Well-designed clinical trials possibly related to Tnkase (Tenecteplase)
Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction). [2011.06]
Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. [2011.05.10]
Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. [2011.01]
Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention. [2011.01]
Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. [2010.09]
Left ventricular function in acute myocardial infarction treated with thrombolysis followed by early versus late invasive strategy. [2010.07]
Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). [2010.01.12]
Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. [2010.01]
Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. [2009.07.30]
Routine early angioplasty after fibrinolysis for acute myocardial infarction. [2009.06.25]
Thrombolysis during resuscitation for out-of-hospital cardiac arrest. [2008.12.18]
Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. [2008.04]
Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventricular function after acute myocardial infarction? [2007.07]
Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. [2007.06.05]
Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. [2007.04]
Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the Gracia 2 non-inferiority, randomized, controlled trial. [2007.01.23]
The NORwegian study on DIstrict treatment of ST-elevation myocardial infarction (NORDISTEMI). [2007.01]
Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? [2007.01]
Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. [2006.11.10]
Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction. [2006.08]
The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction. [2006.06]
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. [2005.11]
Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). [2005.08.02]
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. [2004.07.07]
A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial). [2004.06]
International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. [2003.09]
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. [2003.08]
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. [2003.02]
Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. [2003]
Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. [2002.04.23]
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. [2002.04.09]
Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. [2002.02]
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. [2001.12]
Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. [2001.11.27]
Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. [2000.12.15]
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. [2000.11.07]
Other research related to Tnkase (Tenecteplase)
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. [2012]
Prehospital administration of tenecteplase for ST-segment elevation myocardial infarction in a rural EMS system. [2011.10]
[Massive pulmonary embolism treated with selective infusion of tenecteplase]. [2011.09]
A new therapeutic strategy for acute ischemic stroke: sequential combined intravenous tPA-tenecteplase for proximal middle cerebral artery occlusion based on first results in 13 consecutive patients. [2011.06]
Tenecteplase in the treatment of acute pulmonary thrombo-embolism. [2011.05]
In vitro stability and compatibility of tenecteplase in central venous access devices. [2011.04]
Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4. [2011.01]
ST segment resolution in patients with tenecteplase-facilitated percutaneous
coronary intervention versus tenecteplase alone: Insights from the Combined
Angioplasty and Pharmacological Intervention versus Thrombolysis ALone in Acute
Myocardial Infarction (CAPITAL AMI) trial. [2010]
Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial. [2009.09.01]
Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry. [2009.09]
Role of tenecteplase in pulmonary embolism. [2009.09]
"Tenecteplase--the best among the equals.". [2009.09]
TNK-tPA (tenecteplase). [2009.09]
Massive pulmonary embolism immediately diagnosed by transthoracic echocardiography and treated with tenecteplase fibrinolysis. [2009.08]
Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. [2009.03.10]
An unusual presentation of massive pulmonary embolism mimicking septal acute myocardial infarction treated with tenecteplase. [2009.02]
Sequential combination of two intravenous thrombolytics (recombinant tissue plasminogen activator/tenecteplase) in a patient with stroke and cardioembolic basilar artery occlusion. [2009.01]
Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. [2009]
Successful prolonged resuscitation involving the use of tenecteplase without neurological sequelae. [2008.11]
Efficacy and safety of tenecteplase in Indian patients with st-segment elevation myocardial infarction. [2008.11]
Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy. [2008.09.01]
Successful treatment of ventricular assist device associated ventricular thrombus with systemic tenecteplase. [2008.06]
Low-dose tenecteplase during cardiopulmonary resuscitation due to massive pulmonary embolism: a case report and review of previously reported cases. [2007.10]
Tenecteplase to treat pulmonary embolism in the emergency department. [2007.04]
Tenecteplase for malignant pericardial effusion. [2007.02]
The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. [2007]
Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase. [2006.12]
Case of the month: A case of airway obstruction following tenecteplase administration. [2006.10]
Vocal cord haematoma after tenecteplase thrombolysis. [2006.08]
Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. [2006.06]
Tenecteplase in acute lower-leg ischemia: efficacy, dose, and adverse events. [2006.04]
Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase. [2005.11]
Tenecteplase in the treatment of thrombosed hemodialysis grafts. [2005.07]
[Tenecteplase for massive pulmonary embolism in a 92-year-old man] [2005.06]
A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. [2005.03]
The platelet-related effects of tenecteplase versus alteplase versus reteplase. [2005.01]
Case report. Successful use of tenecteplase in massive pulmonary embolism with cardiopulmonary resuscitation immediately following tracheostomy. [2005]
Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model. [2004.12]
Tenecteplase and return of spontaneous circulation after refractory cardiopulmonary arrest. [2004.10]
|
